VLP Binding Agents for Parvovirus B19 Detection and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective vaccine or treatment for human erythrovirus, including parvovirus B19, which can cause severe diseases in fetuses, newborns, and immunocompromised individuals, and there is no available prevention or cure for these infections.
Innovation Solution
Development of virus-like particle (VLP) binding agents, such as antibodies and monoclonal antibodies, that specifically bind to parvovirus, erythrovirus, or parvovirus B19, including wild-type and mutant VLPs, for detection, diagnosis, and treatment, using specific amino acid modifications in the VP2 polypeptide to target the virus effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no vaccine or treatment is available for parvovirus B19, then prevention and cure options are lacking, but this leaves patients vulnerable to severe diseases
Solution Approach 1:
The patent creates virus-like particles (VLPs) that are copies of the actual parvovirus B19 structure but without the harmful genetic material. These VLPs replicate the viral capsid structure to elicit immune responses and enable detection, providing both vaccine and diagnostic capabilities without the risks of live virus exposure
Solution Approach 2:
The patent introduces VLP binding agents (antibodies) as intermediaries that specifically recognize and bind to parvovirus B19 and its VLPs. These binding agents serve as mediators for both prevention (by neutralizing the virus) and detection (by enabling diagnostic assays), bridging the gap between the virus and the immune system or detection systems
2Measurement precision
If VLP binding agents are developed to detect and treat parvovirus B19, then diagnostic and therapeutic capabilities are improved, but the complexity of the solution increases
Solution Approach 1:
The patent focuses on developing binding agents with specificity for local epitopes on the VLP surface. By targeting specific regions (such as particular amino acid sequences on the capsid proteins), the binding agents achieve high detection precision and therapeutic effectiveness without requiring complex multi-component systems
Solution Approach 2:
The VLP binding agents are designed to perform multiple functions: they can neutralize the virus for therapeutic effect, detect the virus for diagnostic purposes, and potentially serve as vaccine components. This multi-functionality reduces the need for separate systems for prevention and detection, simplifying the overall approach despite the molecular complexity of the binding agents
Data Source
AI summary
Some embodiments of the invention include virus-like particle (VLP) binding agents, and related polynucleotides, cells, methods of making, and compositions. Other embodiments of the invention include methods of detecting VLPs, parvovirus, erythrovirus or parvovirus B19 using a VLP binding agent and diagnostic methods for parvovirus, erythrovirus or parvovirus B19. Further embodiments include methods for administering VLP binding agents to an animal. Other embodiments include treating parvovirus, erythrovirus or parvovirus B19 infections and other diseases. Additional embodiments of the invention are also discussed.